ABN AMRO Bank N.V. Invests $897,000 in Amgen Inc. $AMGN

ABN AMRO Bank N.V. bought a new stake in Amgen Inc. (NASDAQ:AMGN) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 3,190 shares of the medical research company’s stock, valued at approximately $897,000.

A number of other hedge funds have also recently modified their holdings of AMGN. Brighton Jones LLC boosted its stake in Amgen by 23.5% in the fourth quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock valued at $7,159,000 after acquiring an additional 5,226 shares in the last quarter. Sivia Capital Partners LLC lifted its holdings in shares of Amgen by 10.6% in the 2nd quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company’s stock valued at $331,000 after purchasing an additional 114 shares during the last quarter. Sax Wealth Advisors LLC boosted its position in shares of Amgen by 20.9% in the 2nd quarter. Sax Wealth Advisors LLC now owns 1,254 shares of the medical research company’s stock valued at $350,000 after purchasing an additional 217 shares during the period. REAP Financial Group LLC boosted its position in shares of Amgen by 201.6% in the 2nd quarter. REAP Financial Group LLC now owns 184 shares of the medical research company’s stock valued at $51,000 after purchasing an additional 123 shares during the period. Finally, Bar Harbor Wealth Management grew its stake in Amgen by 13.5% during the 2nd quarter. Bar Harbor Wealth Management now owns 2,816 shares of the medical research company’s stock worth $786,000 after buying an additional 335 shares during the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

Amgen Stock Performance

Shares of AMGN opened at $367.80 on Friday. The stock has a market capitalization of $198.05 billion, a P/E ratio of 25.85, a P/E/G ratio of 3.20 and a beta of 0.46. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.99 and a current ratio of 1.14. Amgen Inc. has a 1 year low of $261.43 and a 1 year high of $374.90. The company’s fifty day moving average is $333.66 and its two-hundred day moving average is $310.84.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, beating the consensus estimate of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The business had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. During the same quarter in the previous year, the firm earned $5.31 earnings per share. The business’s quarterly revenue was up 8.6% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, sell-side analysts predict that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, February 13th will be given a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a yield of 2.7%. The ex-dividend date is Friday, February 13th. This is a positive change from Amgen’s previous quarterly dividend of $2.38. Amgen’s payout ratio is presently 66.90%.

Insider Transactions at Amgen

In other Amgen news, EVP Murdo Gordon sold 6,879 shares of the stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $336.83, for a total value of $2,317,053.57. Following the completion of the transaction, the executive vice president owned 41,923 shares in the company, valued at approximately $14,120,924.09. This represents a 14.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Rachna Khosla sold 890 shares of the firm’s stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $336.24, for a total value of $299,253.60. Following the completion of the sale, the senior vice president directly owned 7,082 shares of the company’s stock, valued at approximately $2,381,251.68. This trade represents a 11.16% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 10,908 shares of company stock valued at $3,674,966. Corporate insiders own 0.76% of the company’s stock.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Q4 results beat Street estimates and management issued a robust 2026 outlook, driven by double‑digit revenue and EPS growth and strong new‑product uptake — a primary driver of the rally. Amgen Q4 results beat Street estimates
• Positive Sentiment: Several brokerages raised price targets (notably Goldman Sachs to $415 and RBC/Leerink upgrades), lending credibility to upside expectations and supporting institutional buying interest. Goldman Sachs adjusts price target on Amgen
• Positive Sentiment: Momentum indicators and flow show Amgen near 52‑week highs with reports of institutional accumulation, reinforcing sentiment that the company’s growth trajectory is being re‑rated. Amgen Stock Hits 52-Week Highs: Buy Signal?
• Neutral Sentiment: Amgen reported completion of postmarketing work on IMLYGIC’s melanoma safety study and updates on the FORTITUDE‑301 trial; these procedural milestones reduce uncertainty but are unlikely to move the needle until detailed data or regulatory actions follow. IMLYGIC safety study reaches completion
• Neutral Sentiment: Analyst coverage is mixed: some firms reiterate holds or lower relative targets even as others are bullish, creating a split narrative on valuation vs. execution risk. Analyst: new-product uptake offset by legacy erosion
• Negative Sentiment: CVS Health will remove Amgen and Lilly bone‑disease treatments from some preferred drug lists effective April 1, substituting lower‑cost alternatives — a clear near‑term sales headwind for affected products and a reason for investor caution. CVS to drop Amgen and Lilly bone disease treatments

Analyst Ratings Changes

AMGN has been the subject of a number of research reports. The Goldman Sachs Group boosted their price objective on Amgen from $403.00 to $415.00 and gave the company a “buy” rating in a research note on Wednesday. Citigroup lifted their target price on shares of Amgen from $315.00 to $345.00 and gave the company a “neutral” rating in a report on Wednesday. UBS Group increased their price target on shares of Amgen from $380.00 to $390.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. DZ Bank raised their price objective on shares of Amgen from $335.00 to $364.00 in a research report on Monday, November 10th. Finally, Cantor Fitzgerald upped their target price on shares of Amgen from $315.00 to $350.00 and gave the company a “neutral” rating in a report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $347.65.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.